Clinical Trials

2 trials
RecentStart dateEnrollment
Anemia, Refractory, with Excess of Blasts × Basiliximab × Clear all
NCT00975975 2016-02-26

Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer

Indiana University

Phase 2 Completed
17 enrolled 9 charts
Classical hematologyLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Aplastic, Anemia, Refractory, with Excess of Blasts, Hemoglobinuria, Paroxysmal, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Primary Myelofibrosis

NCT00594308 2014-10-06

In-Vivo Activated T-Cell Depletion to Prevent GVHD

Indiana University

Phase NA Terminated
10 enrolled 11 charts
Classical hematologyLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Refractory, with Excess of Blasts, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Primary Myelofibrosis